MARKET

TSHA

TSHA

Taysha Gene Therapies, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.82
-0.83
-10.85%
Closed 16:00 01/27 EST
OPEN
7.87
PREV CLOSE
7.65
HIGH
7.97
LOW
6.68
VOLUME
225.66K
TURNOVER
--
52 WEEK HIGH
32.39
52 WEEK LOW
6.68
MARKET CAP
366.23M
P/E (TTM)
-1.7783
1D
5D
1M
3M
1Y
5Y
Taysha Gene Plans Protocol Amendment After Patient Death In Gene Therapy Trial
Taysha Gene Therapies Inc (NASDAQ: TSHA) reported 
Benzinga · 6h ago
Taysha posts early biomarker data for gene therapy in GM2 gangliosidosis
Taysha Gene Therapies (NASDAQ:TSHA) announced encouraging initial biomarker data for its experimental gene therapy TSHA-101 in patients with Sandhoff and Tay-Sachs diseases, two forms of GM2 gangliosidosis. The Hex A
Seekingalpha · 10h ago
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, The First Bicistronic Gene Therapy In Clinical Development, Demonstrating Normalization Of β-Hexosaminidase A Enzyme Activity In Patients With GM2 Gangliosidosis
Patient 1 with Sandhoff disease realized normalization of Hex A enzyme activity by Month 1, achieving 58-fold above the presumed asymptomatic level of 5% of normal identified by natural history at Month
Benzinga · 11h ago
Taysha Gene Therapies Reports Positive Results for TSHA-101 to Treat Sandhoff, Tay-Sachs Diseases
MT Newswires · 12h ago
8 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio
In this article, we will take a look at some of the stocks in Eashwar Krishnan’s Tybourne Capital Management portfolio. You can skip our detailed discussion and go to see 5 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio. Eashwar Krishna...
Insider Monkey · 01/12 13:00
Taysha Gene Therapies Announces January 2022 Virtual Investor Events To Review Preliminary Clinical Data For TSHA-101 In GM2 Gangliosidosis And High Dose Cohort And Long-Term Clinical Data For TSHA-120 In Giant Axonal Neuropathy
Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central
Benzinga · 12/28/2021 12:04
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.
Benzinga · 12/26/2021 14:53
Taysha shares early safety data for first-generation construct in rare neuro disease
Announcing the preliminary clinical safety data for the company’s first-generation construct in CLN7 disease, Taysha Gene Therapies (NASDAQ:TSHA) said that the experimental therapy demonstrated a favorable tolerability and safety profile
Seekingalpha · 12/22/2021 12:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TSHA. Analyze the recent business situations of Taysha Gene Therapies, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

46.15%Strong Buy
53.85%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TSHA stock price target is 42.75 with a high estimate of 60.00 and a low estimate of 28.00.
High60.00
Average42.75
Low28.00
Current 6.82
EPS
Actual
Estimate
-1.08-0.81-0.54-0.27
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 46
Institutional Holdings: 18.80M
% Owned: 35.00%
Shares Outstanding: 53.70M
TypeInstitutionsShares
Increased
21
1.78M
New
4
748.35K
Decreased
11
298.59K
Sold Out
5
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.70%
Pharmaceuticals & Medical Research
+0.35%
Key Executives
President/Chief Executive Officer/Director
Ra Session
Chief Financial Officer
Kamran Alam
Other
Suyash Prasad
Independent Director
Phillip Donenberg
Independent Director
Paul Manning
Independent Director
Sukumar Nagendran
Independent Director
Sean Nolan
Independent Director
Kathleen Reape
Independent Director
Laura Sepp-Lorenzino
No Data
About TSHA
Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its product candidates include: TSHA-101, which is being developed for the treatment of GM2 gangliosidosis; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter; TSHA-102, which is being developed for the treatment of Rett syndrome; TSHA-103, which is being developed for the treatment of Solute Carrier Family 6 Member 1 (SLC6A1) haploinsufficiency disorder, and TSHA-104, which is being developed for the treatment for Surfeit locus 1.

Webull offers kinds of Taysha Gene Therapies Inc stock information, including NASDAQ:TSHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TSHA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TSHA stock methods without spending real money on the virtual paper trading platform.